Loading clinical trials...
Loading clinical trials...
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Conditions
Interventions
Dabrafenib
Trametinib
+2 more
Locations
20
United States
Novartis Investigative Site
Scottsdale, Arizona, United States
Novartis Investigative Site
San Francisco, California, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
Chapel Hill, North Carolina, United States
Start Date
December 19, 2012
Primary Completion Date
June 18, 2020
Completion Date
June 18, 2020
Last Updated
October 29, 2021
NCT05673200
NCT05245812
NCT04929028
NCT04550494
NCT05198830
NCT05691465
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions